Teleios Health Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.3/10
Best for: seeing what it charges before you answer any medical questions
Teleios Health falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Teleios Health markets compounded semaglutide from $99/mo and compounded tirzepatide from $139/mo, among the lowest published in the cash-pay segment. Intake is fully online and medication is delivered direct to the door. The physician-led platform emphasizes MD/DO prescribing rather than an NP-only model. Maintenance-dose pricing and other plan details are not surfaced publicly.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Teleios Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Teleios Health at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo
- FDA status
- No FDA warning letter on record
How Teleios Health scores
Six columns, each one computed from something Teleios Health has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
5.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is low.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Teleios Health
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: low.
What signing up with Teleios Health involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Teleios Health publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Teleios Health does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether Teleios Health serves your state cannot be confirmed from its site.
GLP-1 medications Teleios Health offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off Teleios Health's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Teleios Health charges
Teleios Health lists $99/month. That sits at the affordable end of what we track.
- semaglutide — $99/month
- tirzepatide — $139/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Teleios Health is genuinely under the middle rather than merely advertising that it is.
TRYM Health dispenses semaglutide and tirzepatide from $96/month, which makes it the honest comparison to run before committing here.
What Teleios Health dispenses
Teleios Health prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data.
What we could verify
Teleios Health publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
Teleios Health competes on price and does it without an obvious sacrifice elsewhere: $99/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Teleios Health falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Teleios Health
Starting at $99/month. Check today's price, then book the free consultation.
Where Teleios Health is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Teleios Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Teleios Health's current pricing
Plans start at $99/month. The free consultation is where you learn whether you qualify, and what it costs today.